

## REFERÊNCIAS BIBLIOGRÁFICAS

- Ahrens TF, Pettit JETS, Ridley DS, Glaus L 1975. Multicentre controlled comparative trial of Clofazimine and Dapsone in low dosages. *Lepr Rev* 46: 287.
- Andrade VLG, Boechat AM, Viana FR et al 1993. Estudo do índice baciloscópico em pacientes de Hanseníase Multibacilares durante tratamento com esquema MDT/OMS e no período de dois anos após a interrupção da terapêutica. *An Bras Dermatol* 68 (4): 191-193.
- Azulay RD 1978. *Hanseníase: da imunobiologia a imunopatologia*. Rio de Janeiro. Tese de Professor Titular do Departamento de Clínica (Disciplina de Dermatologia) da Faculdade de Medicina da Universidade Federal do Rio de Janeiro.
- Azulay RD, Da Silva NC, Zeo A, De Jesus M, Franca CB 1975. Personal experience with Clofazimine in the treatment of leprosy. *Lepr Rev* 46. Suppl.: 99-103.
- Bahong J, Levy L, Grosset J 1996. Chemotherapy of leprosy. Progress since Orlando Congress and the Prospects. In: International Workshop on Leprosy Research Bangkok, 1996, Thailand.
- Bahong J, Perani EG, Petinon C, Grosset JH 1992. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or Rifampin against *M leprae* in mice. *Int J Lepr other Micobact Dis* 60: 556-656.
- Bechelli LM 1994. Prospects of global elimination of leprosy as a public health problem by the year 2.000. *Int J Lepr other Micobact Dis* 62: 284-292.

Belda W, Margarido LC, Marlet JM et al, 1979. Estudo comparativo das médias móveis, dos índices baciloscópicos e morfológico em pacientes de Hanseníase Virchowiana tratados pela Rifampicina e pela Diamino-Difenil-Sulfona. *Rev Saúde Pública* 13: 80-91.

Beckx - Bleuminck M, 1992. Relapses among leprosy patients treated with multidrug therapy: Experience in the Leprosy Control Programme of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; Practical difficulties with diagnosing operational procedures and criteria for diagnosing relapses. *Int JLepr other Micobact Dis* 60: 421-435.

Becx-Bleumink, M 1994. Success of the WHO multidrug therapy ? *Trop Geogr Med* 46: 61-64.

Becx-Bleumink M, Berhe D 1992. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the Leprosy Control Program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Etiopia. *Int JLepr other Micobact Dis* 60: 173-84.

Brasil. Ministério da Saúde. Departamento Nacional de Saúde. Serviço Nacional de Lepra. 1960. *Manual de Leprologia*. Rio de Janeiro.

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1976. *Legislação em Saúde*. Portaria do MS., nº 165 de 14 de Maio.

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1982. *Controle da hanseníase em serviços básicos de saúde*. In: Congresso Brasileiro de Hansenologia, 4º, Porto Alegre. (Mimeogr.).

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1983. *Guia de Controle da Hanseníase*. Brasília..

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1984. *Relatório final de atividades (período 1982/84) do Comitê Assessor de Peritos em Alternativas Terapêuticas*. Rio de Janeiro.

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1986. Proposta de implantação dos esquemas de poliquimioterapia (OMS).

Brasil. Ministério da Saúde. Divisão Nacional de Dermatologia Sanitária 1989. *Portaria n° 01 de 07 de novembro de 1989. Instruções normativas*.

Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária. 1992. *Instruções Normativas; Regulamentação referente a Portaria Ministerial n° 862/GM de 07/08/92*. Brasília.

Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária. 1993. *Legislação sobre o controle de doenças na área de dermatologia sanitária*. 4. ed. Brasília.

- Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária 1994. *Guia de controle da hanseníase*. 2. ed. Brasília.
- Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária 1995. *Plano de eliminação da hanseníase no Brasil para o período 1995-2000*. Brasília.
- Brasil, 1997. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação Nacional de Dermatologia Sanitária *Informações epidemiológicas e operacionais*. Brasília.
- Brasil MTLRF, Opromolla DVA, Marzliak MLC & Nogueira W 1996. Results of a surveillance system for adverse effects in leprosy's WHO/MDT. *Int JLepr other Micobact Dis* 64: 97-104.
- Browne SG & Hogerzeil LM 1962. "B 633" in the treatment of leprosy: preliminary report of a pilot trial. *Leprosy Rev* 33: 6-10.
- Browne SG, Harman DJ, Waudby H, McDougall AC 1981. Clofazimine (Lamprem, B 663) in the treatment of lepromatous leprosy in the United Kingdom. *Int J.Lepr other Micobact Dis* 49: 167.
- Bullock WE 1983. Rifampicin in the treatment of leprosy. *Rev Infect Dis* 5, suppl.3: 607-611, July- August.

- Cartel JL, Boutin JP, Spiegel A, Roux JF 1991. Longitudinal study of relapse of leprosy in polynesian multibacillary patients. *Lepr Rev*; 62 : 186-192.
- Castro IM, 1978. Adaptação do método de controle da sulfonúria. *Bol Div Nac Dermatol Sanitária* 2 : 43-44.
- Cellona RV, Fajardo Jr TT, Kim D et al 1990. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines and Korea.. *IntJLepr other Micobact Dis* 58: 1-11.
- Convit J 1964. *La therapeutique antilepreuse*. Geneve, Organization Mondiale de la Santé.
- Croft RP 1996. Active surveillance in leprosy: How useful is it? *Lepr Rev* 62 : 135-40.
- Cunha MGS, Pedroza VL & Cruz RCS 1997. Regarding Brasil, et al's adverse effects in leprosy's WHO/MDT and Paramedic's Role in Leprosy Control Program. *Int J Lepr other Micobact Dis* 65: 257-258.
- Cunha MGS, Penini SN, Rebello PB et al, 1993. Fixed duration combined Chemotherapy in Multibacillary Leprosy. *IntJLepr other Micobact Dis* 61, 11 A (Abstract)
- Dean AG, Dean JA, Burton AH, Dicker RC, 1990. Epi Info, version 5:01 a word processing, database, and statistic program for epidemiology on micro-computers. *Centers for Disease Control*, Atlanta, Georgia, USA.

Dubois A 1939. *La lepre : diagnostic, traitement, prophylaxie*. Publié aux Frais de La Comission de La Lépre Etablie par AR. Du 17 Décembre 1937 et vendu au profit des lépreux du Congo Belge et du Ruanda - Urundi. Bruxelles. Imprimerie Industrielle et Financière.

Faget GH, Pogge RC, Johansen FA, Dinan JF, Projean BM, Eccles CG 1943. The promin treatment of leprosy: a progress report. *Public Health Rep* 58: 1729-41.

Gallo MEN, Nery JAC, Garcia CC 1995. Intercorrências pelas drogas utilizadas nos esquemas poli-quimioterápicos em Hanseníase. *Hansenol Int.*, 20 (2): 46-50.

Ganapati R, Pai R, Gandewar KL, Thressia XJ 1989. For how long should a multibacillary leprosy patient be treated ? *Indian JLepr* 61(4): 467-471.

Ganapati R, Pai VV, Shroff HJ & Lailas Gandawar 1997. Rate of decline in bacterial index in leprosy, observations after three different chemotherapeutic. *Int J Lepr other Micobact Dis* 65: 264-266.

Gatner EMS, Anderson R, Van Rensburg CE, Imkamp FMJH 1982. The in vitro and in vivo effects of Clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals. *Lepr Rev* 53: 85.

Glatt R, Alvim MFS 1995. *Situação da hanseníase no Brasil e diretrizes do Plano Nacional de Eliminação*. San José, Costa Rica. Trabalho apresentado no 2º Curso Internacional de Leprologia,

Grosset JH, Guelpa-Lauras CC 1987. Activity of Rifampin in infections of normal mice with *Mycobacterium leprae*. *Int J Lepr other Micobact Dis* 55 suppl.4.

Huang-Yng L, Lu-Fang Hu, Wan-Biao Huang et al 1997. Risk of Relapse in leprosy After Fixed- Duration Multidrug Therapy. *Int J Lepr other Micobact Dis* 62: 238-245.

Huang-Yng L, Xio Lu Y, Mao-Sheng Z et al 1989. Short term multidrug therapy in multibacillary leprosy ; review of 80 cases in two provinces of China (1983-1988). *Int J Lepr other Micobact Dis* 57: 622-627.

Irudayaraj P, Aschhoff M 1989. Assesment criteria and multidrug therapy. *Int J Lepr other Micobact Dis* 57 suppl.: 426.

Jack L Arbiser and Samuel L Moschella, 1995. Clofazimine• a review of its medical uses and mechanisms of action. *JAm Acad Dermatol* 32 (2): 241-246.

Jacobson RR & Trautman JA 1971. The treatment of leprosy with sulphones: the original Faget's 22 patients: a follow up of thirty years under sulphonetherapy for leprosy. *Int J Lepr other Micobact Dis* 39: 71-78.

Jakeman P, Smith WCS, 1994. Evaluation of a MDT programme of leprosy control. *Lepr Rev* 65: 289-296.

Jamet P et al 1992. Short-term trial of Clofazimine in previously untreated lepromatous leprosy. *Int J Lepr other Micobact Dis* 60: 542-548.

- Jamet P, Bahong J & The Marchoux Chemotherapy Study Group 1995. Relapse after long term follow-up multibacillary patients treated by WHO Multidrug Regimen. *Int J Lepr other Micobact Dis* 63: 195-201.
- Jamet P, Blanc L, Faye OC, Traore I, Bobin P 1994. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. *Int other Micobact Dis JLepr* 62:209-214.
- Jopling WH 1976. Complications of treatment with Clofazimine. (Lamprene, B663) *Lepr Rev* 47, 1.
- Jopling WIT 1983. *Manual de lepra*. 1. ed. Rio de Janeiro, Livraria Atheneu.
- Katoch K, Natarjan M, Bagga A, Katoch YM, 1991. Clinical and bacteriological progress of Highly Bacillated BL-LL patients discontinuing treatment after different periods of MDT. *Int J Lepr other Micobact Dis* 59 : 249-254.
- Levy L, Shepard CC & Fasal P 1976. The bactericidal effect of rifampicin on *M. leprae* in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. *Int JLepr other Micobact Dis* 44: 183-187.
- Levy L 1987. Application of the Mouse Foot pad Tecnique in immunological normal mice in support of clinical drug trials and a review of earlier clinical drug trials in lepromatous leprosy. *Int JLepr other Micobact Dis* 55 suppl.4: 823-829.



Marques CFS, Albuquerque ECA, Silva F<sup>o</sup> VF et al 1997. Baciloscopia em casos MB pós 5 anos do esquema PQT/OMS. Comparação entre os valores de IB entre casos reacionais e não reacionais. In: Congresso da Associação Brasileira de Hansenologia, 9, Congresso do Colégio de Hansenologia dos Países Endêmicos, 4. Foz do Iguaçu, 1997.

Martins MVBS 1998. *Papel regulatório da Clofazimina sobre a expressão de moléculas de ativação e secreção de citocinas em células Tc e macrófagos*. Rio de Janeiro. Tese de Mestrado da Universidade Federal do Rio de Janeiro.

Nery JAC 1995. *Reação na hanseníase: uma descrição epidemiológica*. Niterói. Tese de Mestrado da Universidade Federal Fluminense.

Oliveira MLW 1996. *Cura da hanseníase: magnitude das recidivas no Brasil - estudo de coorte de diferentes esquemas terapêuticos e fatores de risco*. Rio de Janeiro. Tese de Doutorado. Universidade Federal do Rio de Janeiro.

Oliveira MLW 1997. A cura da hanseníase x magnitude das recidivas. *A. Bras Dermatol* 72 (1): 63-69.

Opromolla DVA 1972. *Contribuição ao estudo da Terapêutica da Lepra (Hanseníase)* Bauru. Tese de doutorado da Faculdade de Odontologia de Bauru.

Opromolla DVA, Dalpino D, Tonello CJS 1972. Resultados iniciais com Clofazimina no tratamento da lepra. *An Bras Dermatol* 47: 15.

Opromolla DVA, Tonello CJS, McDougall AC et al 1981. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy. *Int J Lepr other Micobact Dis* 49: 393-396.

Pattyn SR 1986. Efficacy of different regimens in multibacillary leprosy. *Lepr Rev* 57 suppl.3: 265- 271.

Pattyn SR, Bourland J, Grillone S et al 1989. Combined regimens of one year duration in the treatment of multibacillary leprosy - I. Combined regimens with Rifampicin administered during one year. *Lepr Rev* 60: 109-17.

Pattyn SR, Bourland J, Kazeze Y 1992. Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration. *Lepr Rev* 63: 36-40.

Pimentel MIF, Borges E, Gonçalves RR, Sarno EN 1997. Importância do tempo de evolução pré-tratamento (PQT) nas incapacidades físicas. *Hansen. Int.*, 22(1): 76 (Abstract).

Pignataro PE, Gallo MEN, , Albuquerque ECA, Nery JAC 1997. Estudo do ILB em biópsias cutâneas de lesões reacionais em casos MB pós PQT/OMS. *Hansen. Int.*, 22(1):103 (Abstract).

Ponninghaus JM & Boerritger G 1995. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy? Results of a trial in Malawi. *Int J Lepr other Micobact Dis* 63: 1-7.

- Ponnighaus, Jorg M, Lienharot Christian, Lucas Sebastian, Fine Paul EM & Sterne Jonathan AC 1997. Comparison of Bacillary Index in slit-skin-smears, skin and nerve biopsies; a study from Malaw. *Int JLepr other Micobact Dis* 65: 211-216.
- Quagliato R, Bechelli LM, Marques RM 1970. Bacterial negativity and reactivation (relapse) of lepromatous outpatients under sulfonic treatment. *Int JLepr other Micobact Dis* 38 : 250-263.
- Rabelo FE 1947. Simpósio sobre a experiência brasileira com sulfonoterapia. *Arq Min Leprol* 12: 285-426.
- Rao PS, Reddy BN, Krishnamurthy P et al 1992. Initial intensive therapy for multibacillary leprosy patients in retrospect. *Lepr Rev* 63: 350-357.
- Reddy PK and Cherian A 1991. Relapse in Hansen's Disease after multidrug therapy and its differential diagnosis with reversal reaction. *The Star*. March/April (8-12).
- Rees RJW, Pearson JMH, Waters MFR 1970. Experimental and clinical studies on rifampicin in treatment of leprosy. *Br Med J* 1: 89-92.
- Ridley DS 1964. Bacterial indices. In: Cochrane RGJ & Daver T et al. *Leprosy in theory and practice*. 2 ed. Bristol, John Wright & Sons. p. 612-622.
- Ridley DS 1971. The SFG (solid fragmented, granular) index for bacterial morphology. *Lepr Rev* 42: 96-97.

Ridley DS, Hilson GRF 1967. A logarithmic Index of Bacilli in Biopsies. *Int J Lepr other Micobact Dis* 35 : 184-186.

Ridley DS, Jopling WH 1966. Classification of leprosy according to immunity; a five group system. *Int J Lepr other Micobact Dis* 34: 255-273.

Rio de Janeiro (cidade) Secretaria Municipal de Saúde. Gerência de Dermatologia Sanitária. Programa de Controle e Eliminação da Hanseníase. 1996. *Relatório*.

Rotberg A 1957. Factor "N" de resistência a lepra e relações com a reatividade leprominica e tuberculínica. Valor duvidoso do BCG na imunização anti-leprosa. *Rev Bras Lepr* 25: 85-100.

Schulz EJ 1972. Forty-four months experience with Clofazimine. *Lepr Rev* 42: 178.

Scollard DM, Smith T, Bhoopat C, et al 1994. Epidemiologic characteristics of leprosy reactions. *Int Lepr other Micobact Dis* 62 : 559-569.

Shepard CC 1960. The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. *JExp Med* 112: 445-454.

Shepard CC 1962. Multiplication of *Mycobacterium leprae* in the foot pad of the mouse. *Int J Lepr other Micobact Dis* 30: 291-306.

Shepard CC, Rees RJ, Levy et al 1986. Susceptibility of strains of *M. leprae* isolated prior to 1977 from patients with previously untreated lepromatous leprosy. *Int J Lepr other Micobact Dis* 54: 11-15.

Talhari S, Damasco MHS, Schettini APM et al 1985. Sulfonoresistência: comparação laboratorial em 6 casos. *An Bras Dermatol* 60(4): 175-178.

Talhari S & Neves RG 1984. *Hansenologia*. Editora Calderaro.

THELEP - Subcommittee on Clinical Trials Scientific Working Group on the Chemotherapy of Leprosy 1986. *Procedures à suivre pour distinguer rechute et reaction reverse dans la lepra paucibacillaire apres l'arret de la polychimiotherapie*. D'après un rapport préparé pour THELEP par D.L. Leiker (rapporteur), M. Christian, P.R. Jacobson, S. Pattyn à Genève, Octobre 1986.

THELEP - Subcommittee on Clinical Trials Scientific Working Group on the Chemotherapy of Leprosy 1987. Persisting *Mycobacterium leprae* among THELEP trial patients Bamako and Chingleput. *Lepr Rev* 58: 325-337.

THELEP - Subcommittee on Clinical Trials Scientific Working Group on the Chemotherapy of Leprosy 1989. Response of THELEP trial patients to combined drug regimens. *Int J Lepr other Micobact Dis* 57: 428 (Abstract).

Tratado de Leprologia, 1950. Rio de Janeiro 2 ed. Rio de Janeiro, Serviço Nacional da Lepra. V.3

- Trindade MAB, Fleury RN, Escuder MHL et al 1997. Evolução histológica de reativação da Hanseníase durante ou após o tratamento. *Hansen. Int.* 22(1): 84 (Abstract).
- Van Brakel WH, Khawas IB, Lucas SB 1994. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. *Lepr Rev* 65: 190-203.
- Vieira LMM, Sampaio EP, Nery JAC, Duppre NC, Albuquerque ECA, Scheinberg MA, Sarno EN 1986. Immunological status of ENL (Erythema nodosum leprosum) patients: its relationship IL- 2R. *Rev Inst Med Trop São Paulo* 38 (2): 103-111.
- Vijayakumaran P, Manimochi N, Jesnudasani K 1995. Incidence of Late Lepra Reaction. Among Multibacillary Leprosy Patients After MDT. *Int J lepr other Micobact Dis* 63 18-22.
- Vischer WA 1969. The experimental properties of G 30, 320 (B 663). *Lepr Rev* 40: 107.
- Ross, WF 1987. A process for planing the introduction and implementation of multidrug therapy for leprosy. *Lepr Rev* 58: 313-323.
- Waters, MFR 1969. G30, 320 (B 663), a working party held in London in September 1968. *Lepr Rev* 40: 21.
- Waters MFR 1986. The rate of relapse in lepromatous leprosy following completion of twenty years of supervised sulphone therapy. *Lepr Rev* 57: 101-107.

- Waters, MFR 1995. Relapse following various types of multidrug therapy in multibacillary leprosy. *Lepr Rev* 66 : 1-9.
- Waters, MFR, Riss RJW 1962. Changes in the morphology of *M. leprae* in patients under treatment. *Int JLepr other Micobact Dis* 36: 266-72.
- WHO - World Health Organization 1991. *Leprosy Programme. MDT ; Questions and answers* . Geneva, WHO/ LTD/ LEP/ 91.3.
- WHO - World Health Organization 1977. *Standard Protocol for chemotherapy trials in lepromatous leprosy*. Geneva, WHO/TDR/SWG THELEP 1: 77-3.
- WHO - World Health Organization 1982. Study Group. *Chemotherapy of Leprosy for Control Programmes* Geneva, WHO. (Technical Reprt Series, 675)
- WHO - World Health Organization 1988. WHO *Expert Committee on leprosy, Sixth Report*. Geneva, WHO. (Technical Report Series, 768)
- WHO - World Health Organization 1993. *Study Group on Chemotherapy of Leprosy*. Geneva.
- WHO - World Health Organization 1994. *Chemotherapy of leprosy*. Geneva, WHO. (Technical Report Series, 847)
- WHO - World Health Organization 1994. The Leprosy Unit Division of Control of Tropical Diseases. *Risk of relapse in leprosy*, Geneva, WHO/LTD/LEP/94.1.

WHO - World Health Organization 1997. *Action Programme for the Elimination of Leprosy*.  
Genebra, WHO.

WHO - World Health Organization 1997. WHO Expert Committee on Leprosy. Geneva, WHO.  
(Technical Report Series, 607)

WHO - World Health Organization 1997. *PQT; perguntas e respostas*. WHO/LEP/97.8.